Abstract
To investigate the function of preferentially expressed antigen of melanoma (PRAME) in esophageal squamous cell carcinoma (ESCC). mRNA expression levels of PRAME were analyzed in resected esophageal tissues of 150 ESCC patients and correlated with clinicopathological parameters. We also investigated the potential function of PRAME by analyzing coordinately expressed genes in 13 ESCC cell lines. RT-qPCR analysis of clinical samples revealed aberrantly high PRAME expression in tumors compared with normal esophageal tissues. High PRAME expression was significantly associated with shorter disease-specific survival and hematogenous recurrence, but not with overall recurrence. The cumulative incidence of hematogenous recurrence was significantly greater for patients with high compared to those with low PRAME expression. In vitro, PCR array analysis revealed that PRAME was coordinately expressed with EGFR, ITGB, and TCF3. PRAME is overexpressed in ESCC tissues and may serve as a novel biomarker for predicting hematogenous recurrence.
Highlights
(ESCC), the latter being the predominant subtype of esophageal carcinoma in Asia and Africa [2]
We investigated the expression of the melanoma-associated antigen (MAGE) family member preferentially expressed antigen of melanoma (PRAME) in esophageal squamous cell carcinoma (ESCC) tissues and showed that it was overexpressed in ESCC compared with adjacent normal esophageal tissues
High tumor PRAME expression was significantly associated with poorer disease-specific survival (DSS), but not disease-free survival (DFS)
Summary
(ESCC), the latter being the predominant subtype of esophageal carcinoma in Asia and Africa [2]. Previous studies have demonstrated an association between the prognosis of ESCC patients and expression of several members of the melanoma-associated antigen (MAGE) gene family, including MAGE-A9 [7], MAGE-A11 [8], and MAGE-D4 [9] Another member of this family, preferentially expressed antigen of melanoma (PRAME), has been reported to play a role in the progression of various malignant tumors, including head and neck squamous cell carcinoma [10,11,12,13,14]. We aimed to assess whether PRAME could have utility as a predictive biomarker for the prognosis of ESCC patients. To this end, we quantified PRAME mRNA in ESCC clinical samples and evaluated its association with disease recurrence patterns and survival. We performed an in vitro analysis to investigate the potential function of PRAME in ESCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
